Notice of Postal Ballot
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Cohance Lifesciences Ltd (formerly Suven Pharmaceuticals) is seeking shareholder approval via postal ballot for the appointment of Mr. Umang Vohra as Chairman (effective May 1, 2026) and Group Chief Executive Officer (effective May 20, 2026) for a 5-year term until April 30, 2031. Vohra is a senior pharma executive with over 10 years at Cipla (MD & Global CEO) and 14 years at Dr. Reddy's (CFO and Head North America generics). The company also seeks approval to pay him remuneration exceeding statutory limits under Section 197 of the Companies Act. Additionally, shareholders are asked to approve the Cohance Lifesciences Limited – Employee Stock Option Plan 2026 (covering up to 2,59,18,613 equity shares), its extension to unlisted subsidiaries, and a specific resolution allowing stock option grants exceeding 1% of issued capital in a single financial year to Vohra. The e-voting period runs from May 15 to June 13, 2026.
Appointment of a high-profile pharma leader with deep industry experience signals a strategic shift toward growth and transformation. The large ESOP grant aligns management incentives with shareholders but may cause dilution. Positive signal for the company's growth trajectory.